Regardless of your long-term view of the stock, the first quarter has ended with not so much as a peep from the company about the status/progress of the testing protocol application and the actual head-to-head hospital test program. I, for one, think that is totally callous and irresponsible on the part of the company.

And while they are at it, an update on the customer testing of the bead samples is long overdue. That lack of investor information is one of several key reasons I won't even consider buying into the stock again, for now, even at these historically low prices. I don't see how it goes up with such investor relations ineptitude.